Meta‐analysis of single‐arm survival studies: a distribution‐free approach for estimating summary survival curves with random effects

In epidemiologic studies and clinical trials with time-dependent outcome (for instance death or disease progression), survival curves are used to describe the risk of the event over time. In meta-analyses of studies reporting a survival curve, the most informative finding is a summary survival curve. In this paper, we propose a method to obtain a distribution-free summary survival curve by expanding the product-limit estimator of survival for aggregated survival data. The extension of DerSimonian and Laird's methodology for multiple outcomes is applied to account for the between-study heterogeneity. Statistics I(2)  and H(2) are used to quantify the impact of the heterogeneity in the published survival curves. A statistical test for between-strata comparison is proposed, with the aim to explore study-level factors potentially associated with survival. The performance of the proposed approach is evaluated in a simulation study. Our approach is also applied to synthesize the survival of untreated patients with hepatocellular carcinoma from aggregate data of 27 studies and synthesize the graft survival of kidney transplant recipients from individual data from six hospitals.

[1]  Gary G Koch,et al.  A non‐parametric procedure for evaluating treatment effect in the meta‐analysis of survival data , 2004, Statistics in medicine.

[2]  Ingram Olkin,et al.  Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta‐analysis with zero cells , 2009, Statistics in medicine.

[3]  B. Vandermeer,et al.  Meta-analyses of safety data: a comparison of exact versus asymptotic methods , 2009, Statistical methods in medical research.

[4]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[5]  S. Senn.  Hans van Houwelingen and the Art of Summing up , 2010, Biometrical journal. Biometrische Zeitschrift.

[6]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[7]  S. Fan,et al.  Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study , 2000, American Journal of Gastroenterology.

[8]  Lu Tian,et al.  Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction. , 2009, Biostatistics.

[9]  T. Tony Cai,et al.  Nonparametric regression in exponential families , 2010, 1010.3836.

[10]  Sylvie Chevret,et al.  Practical methodology of meta-analysis of individual patient data using a survival outcome. , 2008, Contemporary clinical trials.

[11]  F. J. Anscombe,et al.  THE TRANSFORMATION OF POISSON, BINOMIAL AND NEGATIVE-BINOMIAL DATA , 1948 .

[12]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[13]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[14]  P. V. Rao,et al.  Applied Survival Analysis: Regression Modeling of Time to Event Data , 2000 .

[15]  Paula R Williamson,et al.  Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.

[16]  Ian R. White,et al.  Multivariate Random-effects Meta-analysis , 2009 .

[17]  G. Oehlert.  A note on the delta method , 1992 .

[18]  I. White,et al.  Quantifying the impact of between-study heterogeneity in multivariate meta-analyses , 2012, Statistics in medicine.

[19]  V T Farewell,et al.  One-stage parametric meta-analysis of time-to-event outcomes , 2010, Statistics in medicine.

[20]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[21]  George A. Wells,et al.  An Assessment of Methods to Combine Published Survival Curves , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  T. Sauerbruch,et al.  [Sorafenib in advanced hepatocellular carcinoma]. , 2009, Der Internist.

[23]  A new serially correlated gamma-frailty process for longitudinal count data. , 2009, Biostatistics.

[24]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[25]  I. Yoshimura,et al.  A Note on Estimating Treatment Effect for Time-to-event Data in a Literature-based Meta-analysis , 2009, Methods of Information in Medicine.

[26]  Douglas G Altman,et al.  Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls , 2002, The Lancet.

[27]  Dan Jackson,et al.  Extending DerSimonian and Laird's methodology to perform multivariate random effects meta‐analyses , 2009, Statistics in medicine.

[28]  Miguel A Hernán,et al.  The hazards of hazard ratios. , 2010, Epidemiology.

[29]  H Austin,et al.  An exact method for meta-analysis of case-control and follow-up studies. , 2000, Epidemiology.

[30]  Theo Stijnen,et al.  Meta‐analysis of summary survival curve data , 2008, Statistics in medicine.

[31]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[32]  J. Bruix,et al.  A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma , 2010, Hepatology.

[33]  Richard D Riley,et al.  Individual patient data meta-analysis of survival data using Poisson regression models , 2012, BMC Medical Research Methodology.

[34]  Timothée Poisot,et al.  The digitize Package: Extracting Numerical Data from Scatterplots , 2011, R J..

[35]  Paula R. Williamson,et al.  The value of the aggregate data approach in meta‐analysis with time‐to‐event outcomes , 2001 .

[36]  H Putter,et al.  Meta‐analysis of pairs of survival curves under heterogeneity: A Poisson correlated gamma‐frailty approach , 2009, Statistics in medicine.

[37]  K. Dear,et al.  Iterative generalized least squares for meta-analysis of survival data at multiple times. , 1994, Biometrics.

[38]  K. Sung,et al.  Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon‐α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis , 2000, Cancer.

[39]  R B D'Agostino,et al.  Age-adjusted survival curves with application in the Framingham Study. , 1995, Statistics in medicine.

[40]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[41]  E. Kouroumalis,et al.  Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study , 1998, Gut.